BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29786491)

  • 1. Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer.
    Thai JN; Narayanan HA; George AK; Siddiqui MM; Shah P; Mertan FV; Merino MJ; Pinto PA; Choyke PL; Wood BJ; Turkbey B
    Radiology; 2018 Aug; 288(2):485-491. PubMed ID: 29786491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 3. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
    Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
    Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 5. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
    Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
    AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
    [No Abstract]   [Full Text] [Related]  

  • 6. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
    Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
    AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
    [No Abstract]   [Full Text] [Related]  

  • 7. MR Fingerprinting and ADC Mapping for Characterization of Lesions in the Transition Zone of the Prostate Gland.
    Panda A; Obmann VC; Lo WC; Margevicius S; Jiang Y; Schluchter M; Patel IJ; Nakamoto D; Badve C; Griswold MA; Jaeger I; Ponsky LE; Gulani V
    Radiology; 2019 Sep; 292(3):685-694. PubMed ID: 31335285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer: Preliminary Experience.
    Byun J; Park KJ; Kim MH; Kim JK
    J Magn Reson Imaging; 2020 Aug; 52(2):577-586. PubMed ID: 32045072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
    Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
    AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.
    Borofsky S; George AK; Gaur S; Bernardo M; Greer MD; Mertan FV; Taffel M; Moreno V; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    Radiology; 2018 Jan; 286(1):186-195. PubMed ID: 29053402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer.
    Tan N; Lin WC; Khoshnoodi P; Asvadi NH; Yoshida J; Margolis DJ; Lu DS; Wu H; Sung KH; Lu DY; Huang J; Raman SS
    Radiology; 2017 Apr; 283(1):130-139. PubMed ID: 27861110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of prostate cancer in PI-RADS version 2.1 T2-weighted transition zone 'nodule in nodule' and 'homogeneous mildly hypointense area between nodules' criteria: MRI-radical prostatectomy histopathological evaluation.
    Lim CS; Abreu-Gomez J; Flood TA; Carrion I; Dallaire FB; Schieda N
    Eur Radiol; 2021 Oct; 31(10):7792-7801. PubMed ID: 33782767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Cancer: PI-RADS Version 2 Helps Preoperatively Predict Clinically Significant Cancers.
    Park SY; Jung DC; Oh YT; Cho NH; Choi YD; Rha KH; Hong SJ; Han K
    Radiology; 2016 Jul; 280(1):108-16. PubMed ID: 26836049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.
    Ullrich T; Quentin M; Arsov C; Laqua N; Abrar D; Hiester A; Albers P; Antoch G; Schimmöller L
    Rofo; 2020 May; 192(5):441-447. PubMed ID: 31622990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    Mehralivand S; Bednarova S; Shih JH; Mertan FV; Gaur S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2017 Sep; 198(3):583-590. PubMed ID: 28373133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
    Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
    J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
    Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
    J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2.
    Greer MD; Shih JH; Lay N; Barrett T; Kayat Bittencourt L; Borofsky S; Kabakus IM; Law YM; Marko J; Shebel H; Mertan FV; Merino MJ; Wood BJ; Pinto PA; Summers RM; Choyke PL; Turkbey B
    Radiology; 2017 Dec; 285(3):859-869. PubMed ID: 28727501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.